Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03820414 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
A Phase 1 study of Herpes Zoster and Varicella Zoster, sponsored by Curevo.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT03820414 is a Phase 1 study of Herpes Zoster and Varicella Zoster that has completed, run by Curevo. The registered enrollment target is 90 participants, below the 2,168-participant average among 16 other Herpes Zoster trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03820414, a Phase 1 study of Herpes Zoster and Varicella Zoster, has completed, sponsored by Curevo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CRV 101
Study Locations (1)
Missouri
- The Center for Pharmaceutical Research - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2019-01-03 |
| Est. Completion | 2020-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03820414
The ClinicalTrials.gov registry entry for NCT03820414 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,168-participant average among 16 other Herpes Zoster trials with a reported enrollment target (96% lower). The listed sponsor is Curevo, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Herpes Zoster appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03820414 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03820414 about?
NCT03820414 is a clinical study titled "Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects". The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.
What is the current status of trial NCT03820414?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2019-01-03. Estimated completion is 2020-04-30.
What conditions does trial NCT03820414 study?
This clinical trial studies the following conditions: Herpes Zoster, Varicella Zoster.
What interventions are being tested in trial NCT03820414?
The interventions under investigation include: Placebo (BIOLOGICAL), CRV 101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03820414?
This trial is sponsored by Curevo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03820414 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ACTIVE NOT RECRUITING · Phase 1
-
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
COMPLETED · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.